President Trump and his COVID-19 task force have made the production of a vaccine a top priority.
They’ve poured resources into the effort, eliminated burdensome regulations that would delay the process, and promoted quick but safe approval through the FDA.
And it’s all paying off.
Drug manufacturer Moderna – who told the press their vaccine was in “late-stage human trials” last month – has made a huge statement about the potential release date of the COVID cure.
Speaking at a health conference earlier this week, Moderna CEO Stéphane Bancel said Moderna would likely be ready to seek Food and Drug Administration approval for the vaccine for general population use in late January – just three months away!
Bancel noted that they are waiting for the final approval that declares the vaccine is safe and effective. Even if trials are extended, she said, approval is likely by March or early April.
This is record time for a game-changing vaccine, and it’s unlikely that it could have been possible without the investment and incentivizes provided by Trump’s task force.
Moderna is just one of the pharmaceutical giants empowered by the president’s administration to produce results. Pfizer and Johnson and Johnson also worked with the government on a vaccine.
The competition between the companies no doubt inspired this quick delivery – and that was always a part of the plan.
President Trump told a room full of reporters at a COVID-19 briefing in August that “we are investing in the development and manufacture of the top six vaccine candidates to ensure rapid delivery. The military is ready to go, they’re ready to deliver a vaccine to Americans as soon as one is fully approved by the FDA and we’re very close to that approval.”
With this news from Moderna today, it seems this is shaping up to be another “promise made, promise kept” from Trump.